NASDAQ Global Market • Healthcare • Biotechnology • US • USD
Eiger BioPharmaceuticals, Inc. (EIGR) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 11 recommend buying, 0 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
